CMS assigned a specific and permanent reimbursement J-code through the Healthcare Common Procedure Coding System for EyePoint Pharmaceuticals' DEXYCU.
Here are the key details to know:
1. DEXYCU is the first FDA-approved single dose, sustained release intracameral steroid for the treatment of postoperative inflammation.
2. The code, J1095, will become effective Jan. 1, 2019, and will replace the previously issued C-code for DEXYCU (C9034) that became effective Oct. 1, 2018.
3. EyePoint Pharmaceuticals still retains transitional pass-through status for DEXYCU from CMS for approximately three years.